Both the IMpower133 study[9] and the CASPIAN study[10] demonstrated that the combination of programmed cell death ligand 1 (PD-L1) inhibitor (atezolizumab or durvalumab) with platinum and etoposide could extend the overall survival (OS) of ES-SCLC patients by 2–3 months. This evidence concerns the gene CD274 and small cell lung carcinoma.